Positive clinical results of Palobiofarma´s adenosine A1 antagonist PBF-680 presented at the European Respiratory Society meeting.

The results of an allergen POC trial in asthmatics will summarized by Dr. David Ramos, principal investigator of the PBF-680 clinical program, in an oral presentation titled:

PBF-680, an oral A1 adenosine receptor antagonist, inhibits the late allergic response (LAR) in mild-to-moderate atopic asthmatics: a Phase-IIa trial.

The study concluded that in mild-to-moderate asthmatics, PBF-680 abrogated the LAR, and reduced the EAR, FeNO, and, remarkably, blood eosinophils, with correct safety profile. The data position the adenosine modulator PBF-680 as a promising oral asthma therapy.

News

Positive clinical results of Palobiofarma´s adenosine A1 antagonist PBF-680 presented at the European Respiratory Society meeting.

Related News

Palobiofarma announces the enrolment of the first three patients in the clinical study investigating the effects of its novel compound PBF-999 for the treatment of Prader-Willi Syndrome

Palobiofarma announces the completion the Phase II clinical trial with its investigational therapy PBF-680 in chronic obstructive pulmonary disease (COPD) patients.

PBF-999, the first in class treatment in development for the Prader-Willi Syndrome has received “Orphan Drug Designation” by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).

Palobiofarma announces positive results from the Phase II clinical trial evaluating the preliminary efficacy and safety of its adenosine A1 receptor antagonist PBF-680 in mild to moderate asthmatics patients.

XOMA and Inveready Acquires Royalty Interest Position in Six Clinical-Stage Assets from Palobiofarma

Palobiofarma closes a €7M round with the participation of Inveready, Sodena and the Promotor team

PAMPLONA, SPAIN, SEPTEMBER 9th, 2024—Palobiofarma is pleased to announce today positive top-line results in a Phase 2 trial of the novel oral drug PBF-680 in patients with moderate-to-severe COPD.

Palobiofarma S.L. Receives Rare Pediatric Disease Designation from the U.S. FDA for PBF-999 for the Treatment of Prader-Willi Syndrome

November 10th. 2021. Palobiofarma announces positive results in the Phase IIa clinical trial evaluating it´s first in class investigational treatment PBF-677 in patients with mild to moderate ulcerative colitis.

Palobiofarma and Medibiofarma open new headquarters in the AIN building in Cordovilla, Spain